Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanqi Huazhi (also known as Sanqi Huazhi Pills) is a Traditional Chinese Medicine (TCM) formulation primarily developed and studied by The Sixth Affiliated Hospital of Sun Yat-sen University. It is designed for the treatment of internal hemorrhoids, particularly focusing on symptoms such as prolapse and bleeding. The formulation is centered around *Panax notoginseng* (Sanqi), a herb renowned in Chinese medicine for its ability to resolve blood stasis, stop bleeding, and reduce swelling and pain. As a botanical combination, it likely exerts its therapeutic effects through multi-target anti-inflammatory and hemostatic pathways, aiming to improve the clinical grade of hemorrhoidal disease and alleviate patient discomfort. It is typically administered as an oral pill and has been evaluated in randomized, double-blind, placebo-controlled clinical trials.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sanqi Huazhi.